Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Chronic Fatigue Syndrome Linked to Thyroid Levels

By LabMedica International staff writers
Posted on 04 Apr 2018
Print article
Image: The Architect i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Image: The Architect i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Chronic fatigue syndrome (CFS) is a common disease marked by lengthy spells of weakness, fatigue and depression. Its diagnosis is predominantly based on symptoms and on ruling out any underlying medical condition, rather than on laboratory tests and physical examination.

Several symptoms resemble those of hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone. In hypothyroidism, the body tries to encourage thyroid hormone activity by releasing more thyroid-stimulating hormone; however, this does not happen in patients with chronic fatigue syndrome.

Scientists at the University Medical Centre Groningen (Groningen, The Netherlands) collected both blood and urine samples from 98 patients diagnosed with CFS and a total of 99 age- and sex-matched apparently healthy controls. EDTA-whole blood was used for the measurement of routine hematological parameters: hemoglobin (Hb), hematocrit, white blood cells (WBC), red blood cells (RBC), and thrombocytes] with a Sysmex XN-9000 hematology analyzer.

Routine biochemical parameters were measured and these included: Vitamin B12, folate, thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) were assayed by electrochemiluminescent immunoassay on the Roche Modular E170 Analyzer. Serum total thyroxine (TT4) and total triiodothyronine (TT3) were measured using an Architect i2000SR. Serum antithyroglobulin antibodies and antithyroid peroxidase antibodies were measured with an Immulite 2000. Whole blood- and lithium–heparin plasma selenium, copper, magnesium and zinc and iodine in urine were measured using ICP-MS 7700x.

The investigators found that the CFS patients had lower serum levels of certain key thyroid hormones such as triiodothyronine (T3) and thyroxine (T4), but normal levels of thyroid-stimulating hormone. Additional analyses indicated that CFS patients had a lower urinary iodine status and low-grade inflammation, which possibly mirrored the symptoms of patients with hypothyroidism. These CFS patients, however, had relatively higher levels of another thyroid hormone called "reverse T3" or rT3. This appeared to be due to a shift in hormone production, where the body preferred to convert T4 to rT3 instead of producing T3. The low T3 levels found in CFS patients coupled with this switchover to rT3 could mean that T3 levels are severely reduced in tissue.

Begoña Ruiz-Núñez, a PhD student and first author of the study, said, “One of the key elements of our study is that our observations persisted in the face of two sensitivity analyses to check the strength of the association between CFS and thyroid parameters and low-grade inflammation. This strengthens our test results considerably.” The study was published on March 20, 2018, in the journal Frontiers in Endocrinology.

Related Links:
University Medical Centre Groningen

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.